JAN vs. NNVC, BIOR, ACST, ENLV, UBX, ONCT, ITRM, FBRX, LSTA, and RNXT
Should you be buying JanOne stock or one of its competitors? The main competitors of JanOne include NanoViricides (NNVC), Biora Therapeutics (BIOR), Acasti Pharma (ACST), Enlivex Therapeutics (ENLV), Unity Biotechnology (UBX), Oncternal Therapeutics (ONCT), Iterum Therapeutics (ITRM), Forte Biosciences (FBRX), Lisata Therapeutics (LSTA), and RenovoRx (RNXT). These companies are all part of the "pharmaceutical preparations" industry.
NanoViricides (NYSE:NNVC) and JanOne (NASDAQ:JAN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and community ranking.
JanOne has higher revenue and earnings than NanoViricides.
In the previous week, NanoViricides had 2 more articles in the media than JanOne. MarketBeat recorded 7 mentions for NanoViricides and 5 mentions for JanOne. JanOne's average media sentiment score of 0.47 beat NanoViricides' score of -0.05 indicating that NanoViricides is being referred to more favorably in the media.
NanoViricides has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, JanOne has a beta of 2.04, meaning that its share price is 104% more volatile than the S&P 500.
NanoViricides and JanOne both received 0 outperform votes by MarketBeat users.
10.3% of NanoViricides shares are owned by institutional investors. Comparatively, 6.3% of JanOne shares are owned by institutional investors. 4.6% of NanoViricides shares are owned by insiders. Comparatively, 3.0% of JanOne shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
JanOne's return on equity of -74.66% beat NanoViricides' return on equity.
Summary
NanoViricides beats JanOne on 6 of the 9 factors compared between the two stocks.
Get JanOne News Delivered to You Automatically
Sign up to receive the latest news and ratings for JAN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
